Introduction: Data on statin safety in Asian patients are limited compared with evidence from Western populations.
Asian patients. [7] [8] [9] [10] Recent dyslipidemia treatment guidelines have emphasized the importance of LDL-C lowering with statins for the prevention of CVD, 11, 12 including high-intensity statin therapy to achieve ≥50% reduction in LDL-C. 12 Despite this overwhelming evidence to support lipid lowering through the use of statins to reduce CV risk, dyslipidemia is often undertreated in Asian populations, with reports of up to 60% of high-risk patients not receiving a statin, 13, 14 and low rates of goal attainment in those patients receiving lipid-lowering treatment (~50%), most notably in those at very high CV risk (~30%). 15, 16 Long-term CV outcomes trials with atorvastatin, [17] [18] [19] [20] [21] [22] [23] as well as other statins, 24, 25 have demonstrated the safety of this class in a range of populations. However, compared with the wealth of evidence from Western populations, the availability of statin safety data from Asian populations is limited, which may be a contributing factor in the underutilization of statins for the treatment of dyslipidemia in this ethnic group. Previous retrospective analyses of pooled clinical trial data support the overall safety of atorvastatin across the 10-80-mg dose range. 26, 27 This current retrospective analysis assessed the safety of atorvastatin among Asian patients enrolled in randomized clinical trials.
| METHODS

| Data sources and grouping
There were 101 well-controlled, well-documented Pfizer-sponsored atorvastatin clinical trials that began in or after 1992 and were completed by 30 March 2012. With one exception, 22 these trials are part of a pooled repository database; however, available data from the remaining trial were included in this analysis. A programmatic search for patient race or ethnicity captured on case report forms (CRFs) revealed 58 trials that had enrolled ≥1 patient self-identified as Asian, Oriental, South Asian, Indian, or Pacific Islander.
Data from these 58 trials were grouped by trial duration (Fig. 1 ) so that the several large trials did not confound results from the smaller F I G U R E 1 Identification of Asian patients in randomized clinical trials of atorvastatin. Details of the long-term CV outcomes trials are provided in the footnote to Table 1 . CV, cardiovascular trials. Six long-term trials 18, [20] [21] [22] [23] 28 (see footnote to Table 1 for trial details) investigating the effect of atorvastatin on CV outcomes were analyzed both individually and pooled according to treatment group; the median study duration was 3.1-4.9 years. The remaining 52 shortterm studies (≤2 years) were pooled according to treatment group; the median study duration was 4-72 weeks. All atorvastatin doses (10-80-mg) were investigated ( Fig. 1 ).
| Overall safety analyses
This analysis utilized MedDRA (Medical Dictionary for Regulatory Activities) for adverse event (AE) terms. As MedDRA has been updated during the 20-year period covered by the clinical trial database used for this analysis, and some trials 20, 21, 23 utilized coding dictionaries other than MedDRA, AEs from all trials were mapped to the latest MedDRA terms. Therefore, calculated incidences of AEs for individual trials may differ from rates originally reported.
AEs were collected at each clinic visit based on symptoms reported by the patient, physical examination findings, and abnormal laboratory tests. AEs were reported from initiation of treatment and up to 30 days after trial discontinuation. The intensity of AEs and their relation to study medication were determined by the investigator.
Treatment-related AEs were characterized as possibly, probably, or definitely related to study medication. Any AE for which treatmentrelatedness was not assessed, or was assessed as unknown on the CRF, was considered related to study drug. Serious AEs (SAEs) were 
| Statistical analyses
The goal of this analysis was to summarize the safety of atorvastatin in Asian patients across the 58 trials; hence, descriptive statistics are
shown for the majority of data. However, for the pooled treatment groups in the long-term CV outcomes trials, baseline characteristics were compared using a chi-square test for categorical variables and t-test for continuous variables, and rates of AEs, SAEs, and discontinuations due to treatment-related AEs/SAEs were compared using logistic regression adjusted for: age (<70 vs ≥70 years of age); current smoking status; body mass index (BMI); systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL-C, total cholesterol, and serum creatinine levels; and history of coronary artery bypass graft, coronary angioplasty, CVD, diabetes, myocardial infarction, or hypertension. Statistical analyses were performed using SAS 9.2 or later (SAS Institute, Cary, NC, USA). Two-sided P-values < 0.05 were considered statistically significant.
| RESULTS
| Patient population
Overall, of 77 952 patients identified, 3191 (4.1%) were Asian, of whom 2519 received atorvastatin, 300 received placebo, 293 received other statins, and 79 received other lipid-lowering treatments ( Fig. 1 ).
In the six long-term CV outcomes trials, 547 of the 39 172 patients
were Asian, of whom 344 received atorvastatin, 186 received placebo, and 17 received another statin (simvastatin in IDEAL). In the 52 short-term trials, 2644 of the 38 780 patients were Asian, of whom 2175 received atorvastatin, 114 received placebo, 276 received other statins, and 79 received other lipid-lowering treatments.
Baseline variables of Asian patients included in the long-term CV outcomes trials are shown stratified by study in Table S1 , and by treatment group in Table 1 . As in the overall trial populations, 18, [20] [21] [22] [23] 28 treatment and comparator groups for Asian patients in the individual long-term trials were generally well-matched (Table S1 ). There were notable exceptions in some baseline variables such as: age ≥65 years and current smokers in ASCOT-LLA; smoking status and triglyceride levels in ASPEN; age ≥65 years and smoking status in CARDS; age, smoking status, and SBP in IDEAL; age, age ≥65 years, male gender, smoking status, and triglyceride levels in SPARCL; and age ≥65 years in TNT (Table S1 ). Pooled treatment groups for Asian patients in the long-term trials were well-matched (Table 1) , with the exception of higher SBP, DBP, LDL-C, and total cholesterol levels in placebo patients vs patients receiving atorvastatin 10-or 80-mg (all P < 0.05).
Additionally, placebo patients were more likely to be current smokers with a higher BMI and glycosylated hemoglobin level compared with patients receiving atorvastatin 80-mg (all P < 0.05). Patients receiving atorvastatin 10-mg had higher SBP, DBP, total cholesterol, and glycosylated hemoglobin levels, but had lower serum creatinine levels and were less likely to be ≥70 years of age, vs patients receiving atorvastatin 80-mg (all P < 0.05). Baseline variables of Asian patients included in the short-term trials are shown stratified by treatment group in Table 2 . Pooled treatment groups for Asian patients in the short-term trials were well-matched (Table 2) , with the exception that placebo patients were more likely to be older males who were current or exsmokers, with lower cholesterol levels than those in other treatment groups.
| Treatment exposure
Asian patients enrolled in the six long-term CV outcomes trials, in which 106 patients received atorvastatin 80-mg ( Fig. 1) , had a median exposure to atorvastatin of ~3-5 years (Table S2) . For the 52 shortterm trials, where 175 patients received atorvastatin 80-mg ( Fig. 1) , the median exposure to atorvastatin was ~1-3 months (Table S2 ).
| Overall safety
In long-term CV outcomes trials that compared atorvastatin 10-mg with placebo, the proportion of Asian patients who experienced any AE in each of the atorvastatin groups was similar to that observed in the corresponding placebo group (Table 3) . In trials that compared highdose atorvastatin therapy (80-mg) with placebo or lower-dose statin therapy, a higher proportion of Asian patients reported AEs in the atorvastatin 80-mg group compared with the control group in IDEAL and SPARCL (Table 3) ; however, similar AE rates were observed for atorvastatin 80-and 10-mg in TNT. Although the incidence of SAEs between treatment groups varied across trials (Table 3) Table 3 ). However, within each trial, the number of Asian patients who discontinued atorvastatin therapy due to treatment-related AEs/SAEs was ≤8 (Table 3) . When the longterm trials were pooled by treatment group, no significant differences in the rates of AEs, SAEs, or treatment-related AE/SAE discontinuations were seen between treatment groups, with the exception of treatment-related AE/SAE discontinuations in the atorvastatin 80-mg Other statins and other treatments included simvastatin, pravastatin, fluvastatin, lovastatin, cerivastatin, cholestyramine, colestipol, fenofibrate, nicotinic acid, diet therapy, and some combinations.
b Baseline measurements of lipids, BUN, creatinine, and HbA1c were not available for some patients.
c The mean (SD) creatinine of Study A2581045, a multicenter, randomized, open-label, parallel-group, dose-response, 6-week study evaluating the efficacy and safety of atorvastatin 10, 20, 40, and 80 mg in 130 Philippine dyslipidemia patients, was 10.8 (28.6) mg/dL, which was considered as an outlier and therefore excluded from the current analysis.
vs 10-mg group (Table 3 ; P = 0.011); the corresponding atorvastatin 80-mg vs placebo treatment difference did not reach statistical significance (Table 3 ; P = 0.200).
In the 52 short-term trials, Asian patients treated with atorvastatin generally had similar or lower rates of all-causality AEs and SAEs, and discontinuations due to treatment-related AEs/SAEs, compared to those treated with other statins or placebo, with the exception of treatment-related AE/SAE discontinuations in Asian patients who received atorvastatin 80-mg (Table 3 ). In general, higher doses of atorvastatin were associated with higher AE and SAE rates in Asian patients compared with lower atorvastatin doses (Table 3) ; however, a similar proportion of Asian patients who received atorvastatin 10-40-mg discontinued study treatment due to treatment-related AEs/SAEs (Table 3 ). In the pooled short-term trials, Asian patients treated with atorvastatin also had similar or lower rates of AEs, SAEs, and treatment-related discontinuations compared to non-Asian patients (Table S3) . Among the seven body systems investigated (excluding ASCOT-LLA), the most frequently reported all-causality AEs in Asian patients across most trials were gastrointestinal disorders, followed by nervous system disorders (Table S4 ). The incidence of these AEs between treatment groups varied from trial to trial with no evidence of a treatmentor dose-related trend.
| Musculoskeletal safety
Across 57 trials (excluding ASCOT-LLA), there were no cases of rhabdomyolysis in Asian patients treated with atorvastatin (Table S5 ; Fig. 2A) , with one case reported in a patient treated with another statin in a short-term trial (Table S5) (Table S5) , corresponding to myalgia rates of 6.7% (18/270) for atorvastatin ( Fig. 2A ) and 1.9% (2/103) for placebo (Table S5) . Of the 2644 Asian participants in the 52 short-term trials (2175 received atorvastatin), 45 experienced myalgia: 39 received atorvastatin, three received another statin, two received placebo, and one received other therapy (Table S5) , corresponding to myalgia rates of 1.8% (39/2175),
1.1% (3/276), 1.8% (2/114), and 1.3% (1/79), respectively (Table S5 ; Fig. 2A ).
Among the 3034 Asian patients included in the musculoskeletal safety analysis, there was one report of myopathy, in a CARDS patient who received atorvastatin 10-mg (Table S5 ; Fig. 2A ). An elevation of CK >10× ULN occurred in eight atorvastatin-treated c Other statins and other treatments included simvastatin, pravastatin, fluvastatin, lovastatin, cerivastatin, cholestyramine, colestipol, fenofibrate, nicotinic acid, diet therapy, and some combinations.
Asian patients: one patient in IDEAL who received atorvastatin 80-mg and seven patients in the short-term trials (two received atorvastatin 10-mg; five received atorvastatin 40-mg; Table S5 ; Fig. 2A ).
| Hepatic safety
Of the 2740 Asian patients with hepatic safety data, an elevation of ALT >3× ULN occurred in 45 patients who received atorvastatin, with a rate of 2.1% (7/331) in the long-term trials (including ASCOT-LLA; Table S5 ; Fig. 2B ).
| Renal safety
All-causality renal AEs were reported in 1.9% (5/270) of Asian patients who received atorvastatin in the long-term trials (excluding ASCOT-LLA; no placebo cases; Table S5 ; Fig. 2C ), and in one atorvastatin patient (0.05% [1/2175] ) and three placebo patients (2.6% [3/114]) in the short-term trials (Table S5 ; Fig. 2C ). The occurrence of albuminuria, hematuria, microalbuminuria, or proteinuria was infrequent with no evidence of a dose-related trend in Asian patients who received atorvastatin (Table S5 ). No musculoskeletal AE data were available for ASCOT-LLA; hence, the long-term trials included ASPEN, CARDS, SPARCL, IDEAL, and TNT. AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; CK, creatine kinase; ULN, upper limit of normal hypertension, 22 recent myocardial infarction, 21 or stroke. 23 After adjusting for differences in baseline characteristics, no significant differences in the rates of AEs or SAEs were observed between pooled treatment groups; however, there was a higher rate of treatment-related AE/ SAE discontinuations with high-dose atorvastatin (80-mg). It should be noted that-as for the short-term studies-these long-term studies also have varied trial designs, study populations, treatment durations, and treatment arms. Hence, these inferential statistics should be interpreted with caution as the differences in AE rates between treatment arms might be due to differences between study populations and trial durations represented in that treatment group and not due to the treatment per se.
| DISCUSSION
The results of our analysis of atorvastatin safety in Asian patients are consistent with previous analyses of atorvastatin safety in the wider atorvastatin clinical trial population by Newman et al. 26, 27 In an analysis of data from short-term studies (2-78 weeks), 26 all-causality
AEs were experienced by 65% of patients who received atorvastatin at any dose (n = 9416); 51%, 25%, 44%, and 51% of patients in the atorvastatin 10-mg (n = 6343), 20-mg (n = 242), 40-mg (n = 186), and 80-mg (n = 2345) dose groups, respectively, experienced an AE.
A subsequent analysis, 27 which included data from longer-term trials (up to 52 months) and compared low-vs high-dose atorvastatin,
found an incidence of AEs of 53% and 48% in the 10-and 80-mg dose groups, respectively. Our analysis of Asian safety data from pooled short-term trials (4-72 weeks) found that all-causality AEs were experienced by 35% of Asian patients treated with atorvastatin at any dose, with dose-specific AE rates ranging from 28% (atorvastatin 10-mg) to 46% (atorvastatin 80-mg). SAEs were previously reported in ≤10% of atorvastatin patients, and discontinuations due to treatment-related AEs in ≤3% of patients. 26, 27 The corresponding proportions from our analysis of Asian patients enrolled in short-term studies were ≤5% for both SAEs (5.1% for atorvastatin 80-mg; 3.2% across all doses) and discontinuations due to treatment-related AEs/ SAEs (4.6% for atorvastatin 80-mg; 2.0% across all doses). Notably higher proportions of Asian patients experienced all-causality AEs and SAEs, and discontinuations due to treatment-related AEs/SAEs, in the long-term CV outcomes trials (3.1-4.9 years). This may be due to longer durations of exposure increasing the reporting period for AEs, combined with the increased rigor of monitoring and reporting of adverse outcomes associated with CV endpoint trials conducted in high-risk patients, and smaller patient numbers within these treatment groups.
Perceived safety risks related to musculoskeletal, hepatic, and renal AEs may partly explain undertreatment with statins in various patient populations. In this analysis, no direct relationship was observed between atorvastatin dose and incidence of musculoskeletal AEs in Asian patients. The myalgia rate in atorvastatin-treated Asian patients was low and comparable to that observed in the wider atorvastatin clinical trial population (1.8% in short-term studies; 6.7% in long-term trials; ≤4% in previous analyses 26, 27 ). No cases of rhabdomyolysis were observed in atorvastatin-treated Asian patients. Furthermore, incidences of any elevation in ALT or AST >3× ULN were comparable across the previous analyses 26, 27 and this study (≤3%).
Although a growing body of evidence demonstrates the efficacy and safety of atorvastatin in Asian populations of both East Asian 31-37 and South Asian 34, [38] [39] [40] [41] [42] [43] [44] origin, many of these previous studies evaluated the safety profile of atorvastatin doses up to 20-mg over relatively short study durations (6-12 weeks). 31, 33, 35, 36, [41] [42] [43] Statin therapy has been recommended to reduce CVD outcomes in patients at CV risk. 11, 12 This retrospective analysis of pooled AE data from Asian patients in randomized clinical trials provides important additional information on the safety profile of atorvastatin in a previously understudied ethnic group. The consistently low incidence of AEs/SAEs with atorvastatin 10-40-mg, comparable to that of the placebo group, is reassuring, while more studies are needed for atorvastatin 80-mg. The next challenge is to ensure that this evidence is translated into real-world practice to benefit Asian patients at CV risk. 
